Diagnosis and treatment endothelial dysfunction in patients with undifferentiated connective tissue dysplasia

Objective: to determine the level and dynamics of the main markers of endothelial dysfunction in patients with congenital mitral valve prolapse with undifferentiated connective tissue dysplasia, followed by the application and evaluation of efficacy of magnesium. We examined 136 patients, including 61 (41.9%) men and 75 (58.1%) of women aged 15 to 25 (19,5 ± 1,42) years from the primary etiological features PMC. Survey group included 66 (47.7%) patients with MVP with regurgitation of 1 degree and 70 (52.3%) patients with 2 degrees of regurgitation. Patients in each group was administered the drug magnesium (Magnerot firm "Wörwag Pharma") at a daily dose of 3 g. per day for 6 months. Patients with congenital PMC were marked signs of endothelial dysfunction (reduction of nitric oxide, increased endothelin - 1) and damage it (increasing the concentration of vascular endothelial growth factor VEGF). Therapy with magnerot led to an improvement in endothelial function and prevent progression of endothelial damage